Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
Power in Partneringover 1 year ago
The IRA Impact: Navigating Its Evolving Complexitiesover 1 year ago
Fighting for Innovationover 1 year ago
Say Hello to Flexible: Reimagining the Patient Journeyover 1 year ago
Aspiring for the C-Suite? Consider Being a Chief of Staffover 1 year ago
Latent Benefit of Access Restrictions for Rare Conditionsover 1 year ago
The Pharmaceutical Playbook for Asia’s Private Marketover 1 year ago
Operating Models for Successful DOL EngagementNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Stock Becomes UK’s Biggest Stock
2
Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize
3
Basel, Switzerland, Puts Out Call for Pharma Execs
4
HHS and FDA Appoint Richard Pazdur as Director of The Center for Drug Evaluation and Research
5
